Fig. 4From: Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PETKaplan-Meier curves showing the cumulative probability of clinical disease progression. a Plasma/CSF group. b Plasma/PET group. The numbers of individuals at risk at different follow-up time points were presented. Survival time was calculated according to the intervals from the baseline evaluation to the time points of clinical progression. Abbreviations: CSF, cerebrospinal fluid; PET, positron emission tomographyBack to article page